Showing 5231-5240 of 5771 results for "".
- Clearside Biomedical Appoints Dr. George Lasezkay as Interim CEOhttps://modernod.com/news/clearside-biomedical-appoints-dr-george-lasezkay-as-interim-ceo/2476448/Clearside Biomedical announced that its board of directors has appointed biopharmaceutical executive George Lasezkay, Pharm.D., JD, to the position of interim Chief Executive Officer, effective immediately. Dr. Lasezkay, a current member of the Clearside Board of Directors, succeeds Daniel H. Whi
- Avedro’s Corneal Cross-Linking Procedure Now Covered by 65 Coverage Policieshttps://modernod.com/news/avedros-corneal-cross-linking-procedure-now-covered-by-65-coverage-policies/2476444/Avedro announced that four new providers—Providence Health Plan in the Pacific Northwest, Health New England, HealthPartners Minnesota, and Public Employees Health Plan (PEHP) in Utah—have issued positive coverage pol
- Ocutrx Vision Technologies Receives Second Patent for Augmented Reality Glasses Eye Tracking Technologyhttps://modernod.com/news/ocutrx-vision-technologies-receives-second-patent-for-augmented-reality-glasses-eye-tracking-technology/2476434/Ocutrx Vision Technologies, a manufacturer of augmented reality (AR) glasses, announced the issuance of the company’s second US patent, which will protect the company’s unique eye tracking technology for patients with macular degeneration and other low vision conditions. The patent applies to bot
- RightEye Builds Database of One Billion Eye Tracking Data Pointshttps://modernod.com/news/righteye-builds-database-of-one-billion-eye-tracking-data-points/2476433/RightEye LLC announced that it has built a database of more than one billion eye-tracking data points from over 100,000 patient tests conducted using the RightEye system. On track to compile more than two billion data points by year end, major research and health institutions are using the compan
- Lightmed and Mexico’s Leading Pediatric Hospitals Partner in Childhood Blindness Preventionhttps://modernod.com/news/lightmed-and-mexicos-leading-pediatric-hospitals-partner-in-childhood-blindness-prevention/2476428/Lightmed Corp. announced the successful installation and support of 34 LIGHTLas 810 photocoagulator lasers across 32 Mexican states. Mexico’s Ministry of Health initially purchased 18 Lightmed lasers to be placed in areas with the most urgent need. Soon after, they ordered an additional 16 units
- Alcon Adds Topical Local Anesthetic Alcaine 0.5% 15mL to its Ophthalmic Portfoliohttps://modernod.com/news/alcon-adds-topical-local-anesthetic-alcaine-0-5-15ml-to-its-ophthalmic-portfolio/2476426/Alcon announced the latest addition of Alcaine (proparacaine hydrochloride ophthalmic solution, USP) 0.5% 15mL to its procedural eye drops portfolio, which is made up of mydriatic, cycloplegic, diagnostic, and anesthetic products. Alcaine 0.5% 15mL, the only branded proparacaine available,
- Iridex Provides Update on World Glaucoma Congress Activitieshttps://modernod.com/news/iridex-provides-update-on-world-glaucoma-congress-activities/2476427/Iridex announced that its Cyclo G6 glaucoma laser and proprietary MicroPulse Technology were featured in various posters and presentations at the World Glaucoma Congress last week in Melbourne, Australia. The congress ran from March 27- 31, 2019. Eight glaucoma specialists provided hands-o
- Heidelberg Engineering Introduces the GMPE Hood Glaucoma Report for Spectralis OCThttps://modernod.com/news/heidelberg-engineering-introduces-the-gmpe-hood-glaucoma-report-for-spectralis-oct/2479582/Heidelberg Engineering announced that the Hood Glaucoma Report is now available with a software update within the Spectralis OCT Glaucoma Module Premium Edition (GMPE). The GMPE Hood Glaucoma Report highlights
- Stealth BioTherapeutics Doses First Patient in Phase 2 Study of Elamipretide for the Treatment of Dry AMDhttps://modernod.com/news/stealth-biotherapeutics-announces-dosing-of-first-patient-in-phase-2-study-of-elamipretide-for-the-treatment-of-dry-amd/2476423/Stealth BioTherapeutics announced that it has dosed the first patient in ReCLAIM-2, a phase 2 study of elamipretide in patients with dry age-related macular degeneration (AMD) with geographic atrophy. “People with dry AMD can ultimately lose central vision. However, long before that
- First Subjects Enrolled in Clinical Study to Evaluate Safety and Efficacy of OMNI Surgical System for MIGS Procedureshttps://modernod.com/news/first-subjects-enrolled-in-clinical-study-to-evaluate-safety-and-efficacy-of-omni-surgical-system-for-migs-procedures/2476422/Sight Sciences announced that enrollment has begun in the Gemini clinical study, a Sight Sciences-sponsored, prospective, multicenter study to evaluate the safety and efficacy of the OMNI Surgical System in performing two sequential micro-invasive glaucoma surgery (MIGS) procedures—transluminal v